Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor
- 1 December 1996
- journal article
- Published by Elsevier BV in European Journal of Pharmacology
- Vol. 318 (2-3), 429-435
- https://doi.org/10.1016/s0014-2999(96)00795-9
Abstract
This study assesses the importance of metabolites formed following exogenous administration of glucagon-like peptide-1-(7-36) amide (GLP-1). After subcutaneous (s.c.) administration of GLP-1 to dogs the plasma immunoreactivity of GLP-1 measured by two different radioimmunoassays (RIAs) were higher than that measured by a sandwich enzyme-linked immunosorbent assay (ELISA). This discrepancy was due to the formation of the metabolites GLP-1-(9-36) amide, GLP-1-(7-35) and GLP-1-(7-34). Receptor binding studies using baby hamster kidney cells expressing the human pancreatic GLP-1 receptor showed that the affinity of GLP-1-(9-36) amide, GLP-1-(7-35) and GLP-1-(7-34) was 0.95%, 12% and 2.8%, respectively, of the affinity of GLP-1-(7-36) amide. Furthermore, GLP-1-(9-36) amide was shown to be an antagonist to adenylyl cyclase activity, whereas GLP-1-(7-35) and GLP-1-(7-34) were shown to be agonists. GLP-1-(9-36) amide was shown to be present in vivo in amounts up to 10-fold that of GLP-1-(7-36) amide. Due to its low binding affinity, this antagonistic metabolite does not seem to be able to cause physiological antagonism upon s.c. administration of the peptide.Keywords
This publication has 18 references indexed in Scilit:
- Glucagon-like peptide-1(7–37) has a larger volume of distribution than glucagon-like peptide-1(7–36)amide in dogs and is degraded more quickly in vitro by dog plasmaEuropean Journal of Drug Metabolism and Pharmacokinetics, 1996
- Comparison of sandwich enzyme-linked immunoadsorbent assay and radioimmunoassay for determination of exogenous glucagon-like peptide-1(7–36)amide in plasmaJournal of Pharmaceutical and Biomedical Analysis, 1995
- Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivoJournal of Clinical Endocrinology & Metabolism, 1995
- Effect of glucagon-like peptide-1 (proglucagon 78-107amide) on hepatic glucose production in healthy manMetabolism, 1994
- Dipeptidyl‐peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon‐like peptide‐1(7–36)amide, peptide histidine methionine and is responsible for their degradation in human serumEuropean Journal of Biochemistry, 1993
- Structural requirements for biological activity of glucagon‐like peptide‐IInternational Journal of Peptide and Protein Research, 1992
- Antidiabetogenic Effect of Glucagon-like Peptide-1 (7–36)amide in Normal Subjects and Patients with Diabetes MellitusNew England Journal of Medicine, 1992
- Dipeptidylpeptidase IV and trypsin-like enzymatic degradation of human growth hormone-releasing hormone in plasma.JCI Insight, 1989
- Secretin Receptors in Human Pancreatic MembranesPancreas, 1988
- Amino acid sequence and heterogeneity of gastric inhibitory polypeptide (GIP)FEBS Letters, 1981